{"entity":{"id":"sobi","kind":"company","name":"Sobi (Swedish Orphan Biovitrum)","aka":["CTI BioPharma"],"tldr":"Sobi is a Swedish rare-disease company whose haematology and oncology supportive products include palifermin (Kepivance) for severe oral mucositis, avatrombopag (Doptelet) and emapalumab (Gamifant).","summary":"Swedish Orphan Biovitrum markets Kepivance (palifermin) for mucositis after high-dose chemotherapy with stem cell support, Doptelet (avatrombopag) for thrombocytopenia, Gamifant (emapalumab) for haemophagocytic lymphohistiocytosis and Zynlonta (loncastuximab tesirine) in Europe under licence from ADC Therapeutics.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sobi.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["palifermin","emapalumab","pacritinib"],"companies":["adc-therapeutics"],"institutions":[],"pathways":[],"terms":["mucositis","thrombocytopenia"],"trials":["nct07033598"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Stockholm","country":"SE","companyType":"pharma","website":"https://www.sobi.com","ticker":"SOBI.ST","investors":[],"funding":[]},"route":"/companies/sobi/","neighbours":{"drug":[{"id":"emapalumab","kind":"drug","name":"Emapalumab","route":"/drugs/emapalumab/"},{"id":"pacritinib","kind":"drug","name":"Pacritinib","route":"/drugs/pacritinib/"},{"id":"palifermin","kind":"drug","name":"Palifermin","route":"/drugs/palifermin/"}],"company":[{"id":"adc-therapeutics","kind":"company","name":"ADC Therapeutics","route":"/companies/adc-therapeutics/"}],"term":[{"id":"mucositis","kind":"term","name":"Mucositis and stomatitis","route":"/terms/mucositis/"},{"id":"thrombocytopenia","kind":"term","name":"Thrombocytopenia","route":"/terms/thrombocytopenia/"}],"trial":[{"id":"nct00434161","kind":"trial","name":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma","route":"/trials/nct00434161/"},{"id":"nct07033598","kind":"trial","name":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","route":"/trials/nct07033598/"},{"id":"nct00101582","kind":"trial","name":"Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","route":"/trials/nct00101582/"},{"id":"nct00109031","kind":"trial","name":"Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)","route":"/trials/nct00109031/"}]}}